Xeraya Capital, a private equity and venture investor in life sciences, led a $31m Series B round in Aria CV, a developer of medical devices. Also participating in the financing were Longview Ventures, Catalyst Health Ventures, BioStar Ventures, Cedar Point Capital, Frontcourt Group, and three strategic investors. "We’ve worked with Aria CV for several years and are excited for the opportunity to lead this financing. There is an unmet clinical need with patients suffering from pulmonary arterial hypertension, and we are impressed with the promising results the Aria CV PH System has demonstrated. We look forward to being a supportive partner," Jason Rushton, Xeraya Capital Partner.